Jan Meulen

Jan Meulen

Company: Obsidian Therapeutics

Job title: Chief Scientific Officer


Panel Discussion – Engineering Matters to Counter the Tumor Microenvironment (TME) for Better Persistence 2:00 pm

Modifications to achieve blockade of checkpoints (e.g., PD1 KO) or other ligand signalling (e.g., TGFbeta dominant negative) ‘Armouring’ cells with membrane-bound or secreted cytokines Modulation of TME itself to increase tumor ‘warmth’ Dual- and multi-targeting to prevent antigen escape Increasing the safety of therapies by adding ‘switches’ to turn on/off expression of required mattersRead more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.